Discussion
death, lifelong stroke, ventricular cardiomyopathy, HCM, stroke, NVAF
ADVERSE EVENTS, STROKE, REGRESSION
The main findings of this study are: (1) LAAC is a safe and effective stroke prevention treatment with satisfactory outcomes in Chinese NVAF population; (2) The rate of combined death and stroke was 1.93% per-year; (3) Age ≥ 75 yr and the history of ventricular cardiomyopathy were independent risk factors for combined death and stroke after LAAC. This long-term followed cohort provides more representational clinical outcomes for NVAF patients from main land Chinese population.LAAC is an alternative to warfarin or NOACS for lifelong stroke prevention in high-risk patients with NVAF [The LAAC success rate increased from 90.9% in PROTECT to 94.4% in CAP, 95.1% in PREVAIL, 94.8% in CAP2, and reached 98.5% in EWOLUTION [The rate of perioperative adverse events was about 1.19%, significantly lower than MAUDE database [During a median follow-up of 36.9 months (2018 patient-years) in our study. The rate of death and stroke was 1.93% per-year. Meta-analysis outcomes from the PREVAIL and PROTECT AF trials [In multivariate Cox regression analysis, age ≥ 75 (hazard ratio 2.074, 95% CI 1.003–4.285, One review of HCM management [